Spain
· Delayed Price · Currency is EUR Oryzon Genomics Statistics
Total Valuation
Oryzon Genomics has a market cap or net worth of EUR 220.14 million. The enterprise value is 230.73 million.
| Market Cap | 220.14M |
| Enterprise Value | 230.73M |
Important Dates
The last earnings date was Friday, May 9, 2025.
| Earnings Date | May 9, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Oryzon Genomics has 77.51 million shares outstanding. The number of shares has increased by 5.77% in one year.
| Current Share Class | 77.51M |
| Shares Outstanding | 77.51M |
| Shares Change (YoY) | +5.77% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 8.59% |
| Owned by Institutions (%) | 0.29% |
| Float | 62.25M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 6.84 |
| PS Ratio | 29.91 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -54.70 |
| EV / Sales | 31.35 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3.56 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | n/a |
| Revenue Per Employee | 156,569 |
| Profits Per Employee | -89,740 |
| Employee Count | 47 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +43.43% in the last 52 weeks. The beta is 0.44, so Oryzon Genomics's price volatility has been lower than the market average.
| Beta (5Y) | 0.44 |
| 52-Week Price Change | +43.43% |
| 50-Day Moving Average | 2.78 |
| 200-Day Moving Average | 2.09 |
| Relative Strength Index (RSI) | 55.37 |
| Average Volume (20 Days) | 554,585 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Oryzon Genomics had revenue of EUR 7.36 million and -4.22 million in losses. Loss per share was -0.07.
| Revenue | 7.36M |
| Gross Profit | 7.06M |
| Operating Income | -4.74M |
| Pretax Income | -6.12M |
| Net Income | -4.22M |
| EBITDA | -4.61M |
| EBIT | -4.74M |
| Loss Per Share | -0.07 |
Balance Sheet
| Cash & Cash Equivalents | n/a |
| Total Debt | n/a |
| Net Cash | n/a |
| Net Cash Per Share | n/a |
| Equity (Book Value) | n/a |
| Book Value Per Share | n/a |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 95.89%, with operating and profit margins of -64.40% and -57.32%.
| Gross Margin | 95.89% |
| Operating Margin | -64.40% |
| Pretax Margin | -83.22% |
| Profit Margin | -57.32% |
| EBITDA Margin | -62.70% |
| EBIT Margin | -64.40% |
| FCF Margin | n/a |
Dividends & Yields
Oryzon Genomics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.77% |
| Shareholder Yield | n/a |
| Earnings Yield | -1.92% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |